Association of HLA-I supertypes with overall survival of NSCLC patients treated with anti-PD1/PDL1
| HLA-I supertype | Frequency N (%) | HR (95% CI) | P value |
| A24 | 38 (23.6) | 1.34 (0.74 to 2.41) | 0.295 |
| A01 | 71 (44.1) | 0.95 (0.57 to 1.57) | 0.834 |
| A02 | 80 (49.7) | 0.56 (0.34 to 0.93) | 0.023 |
| A03 | 84 (52.2) | 1.27 (0.77 to 2.08) | 0.356 |
| B58 | 13 (8.1) | 0.98 (0.40 to 2.43) | 0.966 |
| B62 | 30 (18.6) | 1.55 (0.80 to 3.00) | 0.137 |
| B27 | 32 (19.9) | 0.91 (0.55 to 1.49) | 0.075 |
| B44 | 90 (55.9) | 0.83 (0.50 to 1.38) | 0.470 |
| B07 | 75 (46.6) | 0.91 (0.55 to 1.49) | 0.705 |
| B08 | 37 (23) | 1.11 (0.60 to 2.07) | 0.724 |
| A01/A24 | 13 (8.1) | 1.29 (0.51 to 3.30) | 0.548 |
HLA, human leukocyte antigen; ;NSCLC, non-small cell lung cancer; PD1/PDL1, programmed cell death protein-1/programmed death ligand 1.